Technical Analysis for HCWB - HCW Biologics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | -3.44% | |
| Wide Bands | Range Expansion | -3.44% | |
| Gapped Up | Strength | -3.44% | |
| Oversold Stochastic | Weakness | -3.44% | |
| Death Cross | Bearish | -2.60% | |
| Doji - Bullish? | Reversal | -2.60% | |
| Wide Bands | Range Expansion | -2.60% | |
| Gapped Up | Strength | -2.60% | |
| Oversold Stochastic | Weakness | -2.60% | |
| Wide Bands | Range Expansion | 0.01% |
| Alert | Time |
|---|---|
| 2x Volume Pace | 11 minutes ago |
| 1.5x Volume Pace | 11 minutes ago |
| 3x Volume Pace | 11 minutes ago |
| 10x Volume Pace | 11 minutes ago |
| Down 5% | 11 minutes ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
HCW Biologics Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation and age-related diseases. The company is involved in developing HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. It is also developing HCW9218 as an injectable immunotherapeutic for patients with pancreatic, breast, ovarian, colorectal, and prostate cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Acute Myeloid Leukemia Immunotherapies Prostate Cancer Leukemia Pulmonary Fibrosis Oncogenes Treatment Of Acute Myeloid Leukemia Age Related Diseases Alopecia Areata
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Acute Myeloid Leukemia Immunotherapies Prostate Cancer Leukemia Pulmonary Fibrosis Oncogenes Treatment Of Acute Myeloid Leukemia Age Related Diseases Alopecia Areata
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.32 |
| 52 Week Low | 0.9 |
| Average Volume | 17,393 |
| 200-Day Moving Average | 1.53 |
| 50-Day Moving Average | 1.52 |
| 20-Day Moving Average | 1.36 |
| 10-Day Moving Average | 1.21 |
| Average True Range | 0.12 |
| RSI (14) | 31.97 |
| ADX | 19.12 |
| +DI | 16.02 |
| -DI | 20.77 |
| Chandelier Exit (Long, 3 ATRs) | 1.31 |
| Chandelier Exit (Short, 3 ATRs) | 1.46 |
| Upper Bollinger Bands | 1.69 |
| Lower Bollinger Band | 1.02 |
| Percent B (%b) | 0.21 |
| BandWidth | 49.48 |
| MACD Line | -0.11 |
| MACD Signal Line | -0.09 |
| MACD Histogram | -0.0208 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.31 | ||||
| Resistance 3 (R3) | 1.31 | 1.27 | 1.29 | ||
| Resistance 2 (R2) | 1.27 | 1.23 | 1.27 | 1.28 | |
| Resistance 1 (R1) | 1.21 | 1.20 | 1.19 | 1.21 | 1.27 |
| Pivot Point | 1.17 | 1.17 | 1.16 | 1.17 | 1.17 |
| Support 1 (S1) | 1.11 | 1.13 | 1.09 | 1.11 | 1.05 |
| Support 2 (S2) | 1.07 | 1.10 | 1.07 | 1.04 | |
| Support 3 (S3) | 1.01 | 1.07 | 1.04 | ||
| Support 4 (S4) | 1.01 |
